{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:49:18Z","timestamp":1791593358182,"version":"4.3.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","award":["unrestricted research grant to AGITG"],"award-info":[{"award-number":["unrestricted research grant to AGITG"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10120-025-01670-2","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:03:25Z","timestamp":1760076205000},"page":"1252-1259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5804-2295","authenticated-orcid":false,"given":"Andrew J.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Yang","family":"Soon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin Marie","family":"Sjoquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Simes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"1670_CR1","volume":"11","author":"Y Tomita","year":"2020","unstructured":"Tomita Y, Moldovan M, Chang Lee R, et al. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. Cochrane Database Syst Rev. 2020;11:CD012078.","journal-title":"Cochrane Database Syst Rev"},{"key":"1670_CR2","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1111\/ans.17249","volume":"91","author":"MN Abbas","year":"2021","unstructured":"Abbas MN, Bright T, Price T, et al. Patterns of care and outcomes for gastric and gastro-oesophageal junction cancer in an Australian population. ANZ J Surg. 2021;91:2675\u201382.","journal-title":"ANZ J Surg"},{"key":"1670_CR3","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1200\/JCO.2015.65.1901","volume":"34","author":"N Pavlakis","year":"2016","unstructured":"Pavlakis N, Sjoquist KM, Martin AJ, et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. J Clin Oncol. 2016;34:2728\u201335.","journal-title":"J Clin Oncol"},{"key":"1670_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10120-017-0754-1","volume":"21","author":"AJ Martin","year":"2018","unstructured":"Martin AJ, Gibbs E, Sjoquist K, et al. Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer. 2018;21:473\u201380.","journal-title":"Gastric Cancer"},{"key":"1670_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12885-023-10642-7","volume":"23","author":"LL Lam","year":"2023","unstructured":"Lam LL, Pavlakis N, Shitara K, et al. Integrate II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory advanced gastro-oesophageal cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). BMC Cancer. 2023;23:180.","journal-title":"BMC Cancer"},{"key":"1670_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.24.00055","volume":"43","author":"N Pavlakis","year":"2025","unstructured":"Pavlakis N, Shitara K, Sjoquist K, et al. Integrate IIa phase III study: regorafenib for refractory advanced gastric cancer. J Clin Oncol. 2025;43:453\u201363.","journal-title":"J Clin Oncol"},{"key":"1670_CR7","unstructured":"Fayers P, Aaronson NK, Bjordal K, et al: EORTC QLQ-C30 scoring manual. Eur Organ Res Treat Cancer 2001."},{"key":"1670_CR8","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1016\/j.ejca.2004.05.023","volume":"40","author":"JM Blazeby","year":"2004","unstructured":"Blazeby JM, Conroy T, Bottomley A, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer. 2004;40:2260\u20138.","journal-title":"Eur J Cancer"},{"key":"1670_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(07)70148-1","volume":"8","author":"MR Stockler","year":"2007","unstructured":"Stockler MR, O\u2019Connell R, Nowak AK, et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol. 2007;8:603\u201312.","journal-title":"Lancet Oncol"},{"key":"1670_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40271-022-00584-w","volume":"15","author":"CD Coon","year":"2022","unstructured":"Coon CD, Schlichting M, Zhang X. Interpreting within-patient changes on the EORTC QLQ-C30 and EORTC QLQ-LC13. Patient. 2022;15:691\u2013702.","journal-title":"Patient"},{"key":"1670_CR11","doi-asserted-by":"crossref","unstructured":"Touraine Cl, Cuer B, Conroy T, et al: When a joint model should be preferred over a linear mixed model for analysis of longitudinal health-related quality of life data in cancer clinical trials. BMC Med Res Methodol 23:36","DOI":"10.1186\/s12874-023-01846-3"},{"key":"1670_CR12","doi-asserted-by":"crossref","unstructured":"Janjigian YY, Kawazoe A, Xu J, et al: Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results. Am Soc Clin Oncol 2024.","DOI":"10.1200\/JCO.2024.42.3_suppl.286"},{"key":"1670_CR13","doi-asserted-by":"publisher","first-page":"e1324","DOI":"10.1093\/oncolo\/oyae087","volume":"29","author":"W Mansoor","year":"2024","unstructured":"Mansoor W, Joo S, Norquist JM, et al. Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer. Oncologist. 2024;29:e1324\u201335.","journal-title":"Oncologist"},{"key":"1670_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100189","volume":"6","author":"E Van Cutsem","year":"2021","unstructured":"Van Cutsem E, Valderrama A, Bang YJ, et al. Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric\/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study. ESMO Open. 2021;6:100189.","journal-title":"ESMO Open"},{"key":"1670_CR15","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1007\/s10120-021-01200-w","volume":"24","author":"E Van Cutsem","year":"2021","unstructured":"Van Cutsem E, Amonkar M, Fuchs CS, et al. Health-related quality of life in advanced gastric\/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. Gastric Cancer. 2021;24:1330\u201340.","journal-title":"Gastric Cancer"},{"key":"1670_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10120-020-01053-9","volume":"23","author":"J Tabernero","year":"2020","unstructured":"Tabernero J, Alsina M, Shitara K, et al. Health-related quality of life associated with trifluridine\/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. Gastric Cancer. 2020;23:689\u201398.","journal-title":"Gastric Cancer"},{"key":"1670_CR17","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.1200\/JCO.23.00170","volume":"41","author":"M Moehler","year":"2023","unstructured":"Moehler M, Xiao H, Blum SI, et al. Health-related quality of life with Nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric\/gastroesophageal junction cancer or esophageal adenocarcinoma from CheckMate 649. J Clin Oncol. 2023;41:5388\u201399.","journal-title":"J Clin Oncol"},{"key":"1670_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103663","volume":"9","author":"F Lordick","year":"2024","unstructured":"Lordick F, Van Cutsem E, Shitara K, et al. Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials. ESMO Open. 2024;9:103663.","journal-title":"ESMO Open"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01670-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01670-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01670-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:01:46Z","timestamp":1791590506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01670-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1670"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01670-2","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"26 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}